An integrated approach to testing and assessment of high aspect ratio nanomaterials and its application for grouping based on a common mesothelioma hazard

Murphy, Fiona and Dekkers, Susan and Braakhuis, Hedwig and Ma-Hock, Lan and Johnston, Helinor and Janer, Gemma and di Cristo, Luisana and Sabella, Stefania and Jacobsen, Nicklas Raun and Oomen, Agnes G. and Haase, Andrea and Fernandes, Teresa and Stone, Vicki (2021) An integrated approach to testing and assessment of high aspect ratio nanomaterials and its application for grouping based on a common mesothelioma hazard. NanoImpact, 22. 100314. ISSN 2452-0748 (https://doi.org/10.1016/j.impact.2021.100314)

[thumbnail of Murphy-etal-NanoImpact-2021-An-integrated-approach-to-testing-and-assessment-of-high-aspect-ratio-nanomaterials-and-its-application]
Preview
 Text. Filename: Murphy_etal_NanoImpact_2021_An_integrated_approach_to_testing_and_assessment_of_high_aspect_ratio_nanomaterials_and_its_application.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (9MB)| Preview

Abstract

Here we describe the development of an Integrated Approach to Testing and Assessment (IATA) to support the grouping of different types (nanoforms; NFs) of High Aspect Ratio Nanomaterials (HARNs), based on their potential to cause mesothelioma. Hazards posed by the inhalation of HARNs are of particular concern as they exhibit physical characteristics similar to pathogenic asbestos fibres. The approach for grouping HARNs presented here is part of a framework to provide guidance and tools to group similar NFs and aims to reduce the need to assess toxicity on a case-by-case basis. The approach to grouping is hypothesis-driven, in which the hypothesis is based on scientific evidence linking critical physicochemical descriptors for NFs to defined fate/toxicokinetic and hazard outcomes. The HARN IATA prompts users to address relevant questions (at decision nodes; DNs) regarding the morphology, biopersistence and inflammatory potential of the HARNs under investigation to provide the necessary evidence to accept or reject the grouping hypothesis. Each DN in the IATA is addressed in a tiered manner, using data from simple in vitro or in silico methods in the lowest tier or from in vivo approaches in the highest tier. For these proposed methods we provide justification for the critical descriptors and thresholds that allow grouping decisions to be made. Application of the IATA allows the user to selectively identify HARNs which may pose a mesothelioma hazard, as demonstrated through a literature-based case study. By promoting the use of alternative, non-rodent approaches such as in silico modelling, in vitro and cell-free tests in the initial tiers, the IATA testing strategy streamlines information gathering at all stages of innovation through to regulatory risk assessment while reducing the ethical, time and economic burden of testing.

CORE (COnnecting REpositories)